null

Enoblituzumab Biosimilar (Anti-B7-H3) Antibody (HDBS0010)

SKU:
HDBS0010
Antibody Type:
Biosimilar Reference Antibody
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Cancer Immunotherapy
Disease Area:
Tumor Microenvironment
Protein:
B7-H3
Reactivity:
Human
Host Species:
Humanized
Isotype:
IgG1
  • Anti-B7-H3 enoblituzumab biosimilar mAb HDBS0010
  • Anti-B7-H3 enoblituzumab biosimilar mAb HDBS0010
  • Anti-B7-H3 enoblituzumab biosimilar mAb HDBS0010
€399

Description

system_update_altDatasheet

Enoblituzumab (Anti-B7-H3) Biosimilar Antibody (HDBS0010)

The Anti-B7-H3 (Enoblituzumab) Biosimilar Antibody (MAB-HDBS0010) is a monoclonal antibody developed for research purposes targeting the B7-H3 protein, a cell surface molecule that plays a vital role in immune regulation and tumor immunity. This biosimilar antibody, derived from Enoblituzumab, binds specifically to the B7-H3 protein, allowing for accurate detection and characterization in various cell types.The B7-H3 protein has been identified as a promising target for cancer immunotherapy due to its role in immune checkpoint regulation and tumor progression.

By targeting B7-H3, researchers can further investigate its function in cancer development and explore potential therapeutic strategies for cancer treatment.This high-quality biosimilar antibody is suitable for a wide range of research applications, including Western blotting, immunohistochemistry, and flow cytometry. Its specificity and sensitivity make it a valuable tool for studying the biological functions of B7-H3 and its potential as a therapeutic target in cancer research.